Head and Neck
Head and Neck
We’re here for you. Call us at 844-346-7222 or
find a clinical trial
If you have any questions or are interested in participating in one of our Clinical Trials, please take note of the associated protocol number and contact our team at (201) 518-3587, or email us at email.
4
Clinical Trials
Head and Neck
Phase II/III
Enrolling
nct/study# NCT06788990 / BCA101X301
A Multicenter, Randomized, Double-Blind, Phase 2/3 Study of BCA101 or Placebo in Combination with Pembrolizumab for First Line Treatment of PD-L1-positive, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Learn More
Head and Neck
Phase III
Enrolling
nct/study# NCT06129864 / D798EC00001-EVOLVE
A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy.
Learn More
Head and Neck
Phase III
Enrolling
nct/study# NCT06496178 / MCLA-158-CL02
A phase III open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator’s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinoma.
Learn More
Head and Neck
Phase III
Enrolling
nct/study# NCT06525220 / MCLA-158-CL03
A phase III randomized, open label study to evaluate the efficacy and safety of Petosemtamab plus Pembrolizumab vs. Pembrolizumab in head and neck squamous cell carcinoma in the first line treatment of PD-L1+ (CPS 1) metastatic/recurrent disease without curative therapy available
Learn MoreWe are here for you
For more information or to schedule an appointment, call (844) 346-7222. You can also schedule an appointment by calling the RCCA location nearest you.
Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.